Progressive Multiple Sclerosis clinical trials

Explore recruiting progressive multiple sclerosis clinical trials.

Recruiting progressive multiple sclerosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Progressive Multiple Sclerosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis

Sweden, Croatia, Norway, Slovakia, France, Lithuania +17 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)

Belgium, France, Austria, Croatia, Portugal, Hungary +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL - TWINS

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 2, randomized, patient and assessor blind, multicentre study comparing foetal neural stem cells transplantation to sham procedure in progressive multiple sclerosis (STEMS2)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis

Denmark, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Melatonin Administration in Patients With Multiple Progressive Primary Sclerosis (MELATOMS)

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Progressive Multiple Sclerosis trials by city

Progressive Multiple Sclerosis in Toronto Progressive Multiple Sclerosis in Vancouver Progressive Multiple Sclerosis in Montreal Progressive Multiple Sclerosis in Calgary Progressive Multiple Sclerosis in Edmonton Progressive Multiple Sclerosis in Ottawa Progressive Multiple Sclerosis in Winnipeg Progressive Multiple Sclerosis in Quebec City Progressive Multiple Sclerosis in Hamilton Progressive Multiple Sclerosis in Kitchener Progressive Multiple Sclerosis in London Progressive Multiple Sclerosis in Halifax Progressive Multiple Sclerosis in New York Progressive Multiple Sclerosis in Los Angeles Progressive Multiple Sclerosis in Chicago Progressive Multiple Sclerosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease